bioMerieux

What bioMerieux does

bioMérieux is a France-headquartered, publicly traded in vitro diagnostics company (Euronext Paris: BIM) founded in 1963 and controlled (~61%) by the Mérieux family through Institut Mérieux. The company develops and manufactures diagnostic instruments, proprietary reagent panels, and software for clinical hospital and reference laboratories, point-of-care settings, food and beverage manufacturers, and pharmaceutical/biopharmaceutical quality control, serving customers in 160+ countries through direct field sales, regional subsidiaries, distributors, and a proprietary eShop.

Its core technology portfolio spans multiplex PCR syndromic testing (BIOFIRE FILMARRAY and BIOFIRE SPOTFIRE), MALDI-TOF mass spectrometry microbial identification (VITEK MS PRIME), automated blood culture (BACT/ALERT VIRTUO and 3D), immunoassays (VIDAS), antimicrobial susceptibility testing (SPECIFIC REVEAL), next-generation sequencing (via Day Zero Diagnostics), automated flow cytometry for cell and gene therapy QC (Accellix), and rapid immunoassay point-of-care testing (SpinChip). Digital/AI capabilities are concentrated in the AUGMENTED-DX web portal, which applies machine learning to contamination source tracing for food manufacturers, and in a 2025 research partnership with Mila for AI-enhanced antibiotic resistance detection.

bioMérieux generates revenue primarily through instrument sales and reagent rental/placement agreements, with the bulk of recurring revenue tied to proprietary consumables and test panels consumed on its installed base across four operating segments: Clinical Diagnostics (€4.07B FY2025 group sales, ~75–80% of mix based on commentary), Food Safety, Pharma QC, and Point-of-Care. Pricing is quote-based and not publicly disclosed; service, software subscriptions, and training programs (bioMérieux University) provide additional recurring revenue and customer lock-in. Recent M&A has been concentrated in point-of-care, cell/gene therapy QC, and NGS-adjacent capabilities, and the company faces near-term softness from weak respiratory panel comparisons, lower China demand, and a €151M Vitek Reveal impairment that compressed FY2025 net income.

Name

bioMerieux

Legal name

bioMérieux S.A.

Website

https://biomerieux.com

Company type

Public

Founded year

1963

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

bioMérieux is a France-based global in vitro diagnostics company that develops proprietary instruments, multiplex PCR panels, and software for clinical labs, point-of-care clinics, food manufacturers, and pharmaceutical QC across 160+ countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

Keywords

• In vitro diagnostics
• Clinical microbiology testing
• Syndromic molecular testing
• Food safety diagnostics
• Pharmaceutical quality control

Headquarters

HQ city

Marcy-l'etoile

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Clinical Diagnostics (In-Hospital / In-Lab): Revenue from sale of diagnostic instruments (BIOFIRE FILMARRAY, BACT/ALERT, VITEK, VIDAS), consumables (reagent test kits, panels), software licenses, and service agreements to hospital laboratories, reference laboratories, and clinical settings globally. Full-year 2025 sales reached €4.07 billion with 6% growth at constant exchange rates.
2. Food Safety & Quality Testing: Sale of molecular testing solutions (GENE-UP, TEMPO, VERIFLOW), consumables, and digital platforms (AUGMENTED-DX, SMARTBIOME) to food and beverage manufacturers across dairy, meat, poultry, seafood, produce, and processed food segments.
3. Pharmaceutical Quality Control: Revenue from pharma manufacturers for sterility testing, mycoplasma detection (BIOFIRE MYCOPLASMA), endotoxin testing (ENDONEXTTM), environmental monitoring (3P ENTERPRISE), and microbial identification (VITEK MS PRIME) solutions used in biopharmaceutical, vaccine, and cell/gene therapy production.
4. Point-of-Care Diagnostics: Sale and placement of BIOFIRE SPOTFIRE systems and panels to outpatient clinics, urgent care centers, pediatric clinics, and general practitioners for syndromic respiratory, gastrointestinal, and joint infection testing at the point of care.
5. Service, Software & Support: Recurring revenue from service agreements, software subscriptions (AUGMENTED-DX portal, digital monitoring platforms), training (bioMérieux University), and lab consultancy services supporting customer retention and long-term contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

bioMérieux develops, manufactures, and markets in vitro diagnostic solutions for clinical, food safety, and pharmaceutical quality control applications. Its portfolio spans multiplex PCR syndromic panels (BIOFIRE FILMARRAY/SPOTFIRE), MALDI-TOF microbial identification (VITEK MS PRIME), automated blood culture systems (BACT/ALERT), immunoassays (VIDAS), and real-time PCR food pathogen detection (GENE-UP), supported by recurring reagent/panel consumables, service contracts, and software platforms such as AUGMENTED-DX.

Product overview

bioMérieux is a global leader in in vitro diagnostics offering an integrated portfolio of diagnostic solutions organized across four main segments: Hospital/Laboratory (clinical microbiology, syndromic testing, immunoassays, blood culture), Point-of-Care (BIOFIRE SPOTFIRE, respiratory/GI panels), Food Safety & Quality (GENE-UP, TEMPO, VERIFLOW, SMARTBIOME), and Pharmaceutical Quality Control (BIOFIRE MYCOPLASMA, BACT/ALERT, environmental monitoring). The portfolio spans from high-throughput laboratory systems like VITEK MS PRIME (mass spectrometry) and BACT/ALERT VIRTUO (blood culture) to rapid point-of-care platforms like BIOFIRE SPOTFIRE for molecular diagnostics in under 15 minutes. Food safety solutions include GENE-UP real-time PCR and the AI-powered AUGMENTED-DX analytics platform. Recent acquisitions (Accellix for flow cytometry, SpinChip for immunoassay, Neoprospecta for genomics) expand capabilities in cell therapy QC, point-of-care testing, and microbiome analysis. The company also offers enterprise software platforms for data integration and environmental monitoring across its customer base.

Differentiator

Problem solved

Functional benefit

Brands

• BIOFIRE: Multiplex PCR syndromic testing platform for infectious disease diagnostics, including FILMARRAY and SPOTFIRE systems
• VITEK
• VIDAS
• BACT/ALERT
• GENE-UP
• SMARTBIOME
• BIOFIRE SPOTFIRE
• ARGENE
• GENE-UP TYPER
• VERIFLOW
• TEMPO
• SPECIFIC REVEAL
• 3P Enterprise
• BIOBALL
• ENDONEXT
• BioFire Defense
• AUGMENTED-DX
• VIDAS Equine

Products and services

• BIOFIRE FILMARRAY System Multiplex PCR technology platform that simultaneously tests for comprehensive groupings of pathogen targets (respiratory, gastrointestinal, bloodstream, meningitis, vaginitis panels) in about an hour, available in TORCH configuration for hospital clinical laboratory settings.
• BIOFIRE SPOTFIRE System Point-of-care molecular testing system based on FILMARRAY technology delivering accurate PCR results in about 15 minutes for respiratory, gastrointestinal, and other infectious disease panels at point-of-care settings including urgent care and pediatric clinics.
• VITEK MS PRIME

Quantifiable outcome

• Early fast diagnostics deployment can reduce reported sepsis cases by >20% across G7 countries and prevent 36,200 deaths and 84,400 sepsis cases annually in the US alone, saving approximately $3 billion annually at ~$3,400 per patient.
• +4 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

Eleven partnerships are on record, tiered minor and core.

• Mérieux NutriSciencesminorStrategic or Co-development Partner · 18 June 2026Mérieux NutriSciences contributed to the development of bioMérieux's GENE-UP TYPER SLM Salmonella testing solution, combining food safety expertise with molecular diagnostics technology to deliver rapid root cause analysis for food manufacturers.
• PlairminorStrategic or Co-development Partner · 27 March 2026bioMérieux invested over CHF 1 million in Plair, a Geneva-based University of Geneva spinoff, to accelerate global rollout of the RAPID-C+ real-time viable particle counter for pharmaceutical environmental monitoring. As part of the deal, bioMérieux Senior Vice President Michael Reynier joined Plair's Board of Directors. The investment endorses RAPID-C+ as a breakthrough innovation for real-time cleanroom monitoring, combining viable and total particle counting with certified continuous sampling on standard agar media.
• AccellixcoreStrategic or Co-development Partner · 23 January 2026bioMérieux acquired 100% of Accellix (a US-based automated flow cytometry company) for approximately €35 million in cash, increasing its stake from ~10% to 100%. Accellix specializes in rapid automated flow cytometry solutions for cell and gene therapy quality control, delivering quality control results in under 30 minutes. The acquisition completes bioMérieux's cell and gene therapy offering by adding cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing capabilities. Accellix employs approximately 70 people across San José, California and Jerusalem, Israel.
• Allergen AlertminorStrategic or Co-development Partner · 5 January 2026Allergen Alert, a spin-off of bioMérieux, developed a portable food allergen detector using single-use pouches derived from bioMérieux's laboratory technologies and immunoassay methods. The technology was initially created through an intrapreneurial program at bioMérieux. The product targets 250 million people worldwide living with food allergies, with interest from Michelin-starred restaurants and corporate catering providers.
• Day Zero DiagnosticsminorStrategic or Co-development Partner · 1 June 2025bioMérieux acquired the assets of Day Zero Diagnostics in June 2025 to enhance its next-generation sequencing (NGS) capabilities, strengthening the company's ability to offer advanced molecular diagnostic solutions for infectious disease detection and characterization.
• Mila (Quebec Artificial Intelligence Institute)minorStrategic or Co-development Partner · 1 April 2025bioMérieux partnered with Mila, an AI research institute, in April 2025 to develop AI-enhanced diagnostic tools focused on antibiotic resistance detection. The collaboration aims to leverage artificial intelligence to improve pathogen identification, antimicrobial susceptibility interpretation, and resistance pattern analysis.
• SpinChip Diagnostics ASAcoreStrategic or Co-development Partner · 1 January 2025bioMérieux acquired Norway-based SpinChip Diagnostics ASA for approximately €138 million ($159.87 million) to strengthen its point-of-care diagnostics portfolio. SpinChip's high-sensitivity immunoassay platform delivers rapid results from whole blood samples in about 10 minutes, complementing bioMérieux's molecular point-of-care offerings with rapid immunoassay technology.
• NeoprospectaminorStrategic or Co-development Partner · 1 January 2025bioMérieux collaborated with Brazil-based Neoprospecta (acquired January 2025), a genomics and data science company, to develop SMARTBIOME — a platform combining high-precision DNA sequencing, bioinformatics, and microbiology expertise to help food manufacturers control microbiological spoilage. The platform is currently available in North America, Latin America, and Europe.
• Pfizer Inc. and Malawi Ministry of HealthminorStrategic or Co-development Partner · 1 May 2024bioMérieux partnered with Pfizer and the Malawi Ministry of Health in May 2024 to enhance infectious disease diagnostics capacity, testing, surveillance, and antimicrobial stewardship in Malawi, supporting the country's healthcare infrastructure and disease monitoring capabilities.
• Boehringer Ingelheim and Evotec SE (Aurobac Therapeutics SAS)coreStrategic or Co-development Partner · 1 July 2022bioMérieux co-founded Aurobac Therapeutics SAS as a joint venture with Boehringer Ingelheim and Evotec SE in July 2022 to create the next generation of antimicrobials alongside actionable diagnostic solutions to tackle the major public health threat of antimicrobial resistance (AMR).
• Specific DiagnosticscoreStrategic or Co-development Partner · 1 May 2022bioMérieux finalized the acquisition of Specific Diagnostics in May 2022, which had developed a rapid antimicrobial susceptibility testing (AST) system (SPECIFIC REVEAL) to complement bioMérieux's clinical microbiology solutions and deliver faster AST results, consistent with its CSR ambition for health by 2025.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• QIAGEN: Leading provider of sample preparation and PCR testing solutions (QIAstat-Dx syndromic panels) directly competing with BIOFIRE in respiratory and GI panels. Overlap with bioMérieux in pharma QC molecular testing and food safety pathogen detection (mericon kits).
• Bio-Rad Laboratories: Direct peer in clinical microbiology with BioPlex 2200, droplet digital PCR, and life science research products. Bio-Rad competes with bioMérieux in quality controls (Bio-Rad's InteliQ), digital PCR, and certain immunoassay segments, with overlap in pharma QC and food safety.
• Cepheid (Danaher): Direct competitor in syndromic molecular diagnostics via the GeneXpert Xpress system and Xpert panels (respiratory, GI, etc.). Cepheid's CLIA-waived Xpress platform competes head-to-head with BIOFIRE SPOTFIRE in urgent care and outpatient settings, with similar multiplex PCR technology and target customer base.
• Hologic: Panther/Panther Fusion molecular diagnostics platform directly competes with BIOFIRE FILMARRAY in hospital labs. Hologic's Aptima women's health assays overlap with the new SPOTFIRE Vaginitis Panel opportunity, making it a particularly relevant competitor as bioMérieux expands into POC women's health.
• QuidelOrtho: Specialty diagnostics company with Sofia and Triage immunoassays, Savanna PCR/NAAT platform, and Ortho clinical chemistry. Direct competitor in POC rapid diagnostics and emerging molecular POC, with comparable customer base in urgent care and outpatient settings.

Broad incumbents

• Roche Diagnostics: Roche's diagnostics division is the global IVD leader with cobas systems, LightCycler PCR, and Elecsys immunoassays. Broadly overlapping with bioMérieux across clinical chemistry, immunoassays, and molecular diagnostics, though Roche operates at much larger scale across the full diagnostics portfolio.
• Thermo Fisher Scientific (Microbiology): Thermo Fisher's Specialty Diagnostics segment, including the Oxoid microbiology range and Remel products, competes with bioMérieux in food safety and pharma QC. The Applied Biosystems QuantStudio and MicroSEQ NGS workflows also overlap with bioMérieux's molecular diagnostics portfolio.
• Becton Dickinson (BD): BD's Diagnostic Systems segment includes BD MAX molecular platform, Phoenix M50 ID/AST, and blood culture products directly competing with bioMérieux's BACT/ALERT and VITEK systems. Broadly comparable across microbiology workflow solutions with a larger overall portfolio including pre-analytics.
• Abbott Diagnostics: Major IVD incumbent with Alinity ci series, m-PIMA POC PCR, and ARCHITECT immunoassays. Overlaps with bioMérieux across clinical chemistry, immunoassays, and molecular POC, particularly in hospital and reference lab markets globally.

Emerging players

• Mesa Labs: Smaller competitor focused on sterilization monitoring, environmental monitoring, and process validation solutions for pharma, medical device, and food safety. Overlaps with bioMérieux's 3P ENTERPRISE environmental monitoring and pharma QC offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/biomerieuxtv
• Facebookfacebook.com/biomerieux
• LinkedInlinkedin.com/company/162715
• Instagraminstagram.com/life.at.biomerieux
• Xx.com/biomerieux

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A25 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bioMerieux